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Abstract: 
Introduction: Despite the use of plasma exchanges and intravenous immunoglobulins, Guillain-Barré syndrome 
(GBS) still carries non-negligible morbidity and mortality. Furthermore, the psychosocial consequences of GBS may 
persist longer than expected. Aims and objectives: The basic objective of the study is to analyze the level of 
hypoalbuminemia as prognostic indicator in GBS patients among local population of Pakistan. Material and 
methods: This descriptive study was conducted in Mayo Hospital, Lahore during March 2018 till October 2018. The 
data were collected from 50 patients of GBS which also include adults and child. The data were divided into two parts 
one include adults and one group include children. Venous blood samples were drawn from all patients within the 
first 24 hours after admission. Complete blood count, renal function test, and hepatic function test were performed 
within 24 hours of hospital admission and before the treatment, and serum CRP, albumin, neutrophil, lymphocyte, 
thrombocyte, CRP, NLR, and PLR levels were recorded. Results: The data were collected from 50 GBS patients. The 
mean age was 48.5±18.95 years in adults and 5±8.21 years in GBS-P. No significant relationship was found between 
NLR, PLR, CRP, and albumin levels and the demyelinating and axonal subtypes in both the GBS-A and GBS-P patient 
groups. In the GBS-P group, on the other hand, the mean NLR level at third month was significantly higher in the 
HDS≥3 group, but there was no significant difference with the other inflammatory markers. Conclusion: It is 
concluded that inflammatory markers including and albumin levels may be used as cheaper, more readily available, 
and more rapidly studied markers for the prediction of the prognosis of GBS.  
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INTRODUCTION: 
Despite the use of plasma exchanges and intravenous 
immunoglobulins, Guillain-Barré syndrome (GBS) 
still carries non-negligible morbidity and mortality. 
Furthermore, the psychosocial consequences of GBS 
may persist longer than expected. Various 
aetiological, clinical, electrophysiological and 
immunological factors may carry prognostic 
predictive value the prognosis of GBS is generally 
considered favourable [1]. In this syndrome, 
autoantibodies triggered by previous infections cross-
react with gangliosides and result in peripheral 
nervous system injury.  Moreover, it has been recently 
shown that inflammatory factors apart from cellular 
and humoral immunity play a role in the GBS 
pathogenesis [2]. Recently, neutrophil–lymphocyte 
ratio (NLR) is known to be widely used as a marker of 
inflammation and a predictor of prognosis in various 
disorders. Higher NLR values were shown to be an 
independent predictor of a worse prognosis among 
patients with acute ischemic stroke, cardiac disorders, 
and cancer. Likewise, increased platelet–lymphocyte 
ratio (PLR) was shown to predict a poor prognosis in 
patients with acute stroke and malignancy [3].  
 
A simple measurement of 
serum albumin concentration could represent a 
prognostic biomarker in patients with Guillain-Barré 
syndrome (GBS) treated with intravenous 
immunoglobulin (IVIG), a new study suggests [4]. 
The study showed that 35% of patients with GBS 
developed hypoalbuminemia 2 weeks after IVIG 
treatment and that low albumin levels after treatment 
were strongly related to a severe clinical course and 
poor outcome. GBS is a post infectious immune-
mediated neuropathy causing rapidly progressive 
weakness of limbs, and respiratory failure in 25% of 
cases. Guillain Barre Syndrome (GBS) is the 
commonest acute predominantly motor neuropathy. It 
comprises of heterogeneous group of disorders of 
presumed autoimmune etiology [5]. 
Aims and objectives 
The basic objective of the study is to analyze the level 
of hypoalbuminemia as prognostic indicator in GBS 
patients among local population of Pakistan. 
 
MATERIAL AND METHODS: 
This descriptive study was conducted in Mayo 
Hospital, Lahore during March 2018 till October 2018. 
The data were collected from 50 patients of GBS 
which also include adults and child. The data were 
divided into two parts one include adults and one 
group include children. Venous blood samples were 
drawn from all patients within the first 24 hours after 
admission. Complete blood count, renal function test, 
and hepatic function test were performed within 24 
hours of hospital admission and before the treatment, 
and serum CRP, albumin, neutrophil, lymphocyte, 
thrombocyte, CRP, NLR, and PLR levels were 
recorded.  
 
Statistical analysis 
The data were collected and analyzed by using SPSS 
version 21.0. All the values were expressed in mean 
and standard deviation. Descriptive statistics included 
mean ± SD, number, and percentage. 
 
RESULTS: 
The data were collected from 50 GBS patients. The 
mean age was 48.5±18.95 years in adults and 5±8.21 
years in GBS-P. No significant relationship was found 
between NLR, PLR, CRP, and albumin levels and the 
demyelinating and axonal subtypes in both the GBS-
A and GBS-P patient groups. In the GBS-P group, on 
the other hand, the mean NLR level at third month was 
significantly higher in the HDS≥3 group, but there was 
no significant difference with the other inflammatory 
markers. In the pediatric group, the mean age of the 
HDS≥3 group was significantly lower than that of the 
HDS<3 group. 
Table 01: Comparisons of inflammatory markers between GBS patients with control groups 
 GBS-A GBS-P p-value 
Age, years 48.50±18.95 5±8.21 0.200 
NLR 3.65±1.73 2.c3±1.89 0.000 
PLR 166.15±64.14 118.37±72.67 0.001 
CRP, mg/dL 0.80±1.48 0.20±0.31 0.001 
Albumin, gr/dL 3.52±0.63 3.98±0.47 0.031 
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DISCUSSION: 
In developing countries, less immunogenic vaccines 
are preferred over highly immunogenic vaccines to 
reduce vaccination costs. This act as a major barrier in 
GBS management in Pakistan. Wali Muhammad et al. 
compared the therapeutic efficacy of Intravenous 
immune globulin (IVIG) with Plasma exchange 
(plasmapheresis) in patients of Acute Inflammatory 
Demyelinating Polyneuropathy i.e., Guillain-Barre 
syndrome (GBS) [6]. They found that both IVIG and 
Plasma Exchange have equal therapeutic efficacy in 
the treatment of patients of GBS [7]. 
GBS is usually diagnosed on the basis of a patient’s 
signs and symptoms with the assistance of laboratory 
cerebrospinal fluid findings and electrophysiological 
criteria. Among GBS patients, the role of some 
biomarkers such as myelin basic protein, 
neurofilaments, anti-ganglioside antibodies, neuron-
specific enolase, hypocretin-1, tumor necrosis factor 
[8], chemokines, and complements in disease 
pathology and prognosis has been examined. There is 
a limited number of studies in the literature which have 
explored the correlation between GBS-A patients and 
serum inflammatory markers [9]. To date, no study has 
assessed the association between GBS-P patients and 
serum NLR, PLR, CRP, and albumin levels [10]. 
 
CONCLUSION: 
It is concluded that inflammatory markers including 
and albumin levels may be used as cheaper, more 
readily available, and more rapidly studied markers for 
the prediction of the prognosis of GBS.  
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